HiRO strengthens US Presence with acquisition of DeltaMed Solutions

HiRO, a leading global clinical research organization (CRO), has announced the successful acquisition of DeltaMed Solutions, a US-based CRO with a strong reputation. This strategic move marks HiRO’s third CRO acquisition since its founding in 2020 and further expands its global footprint.

With established operations in the US, Ireland, Asia, and Oceania, HiRO offers comprehensive clinical research solutions across the globe. The acquisition of DeltaMed Solutions bolsters HiRO’s US presence and strengthens its position as a one-stop shop for pharmaceutical and biotech companies.

Headquartered in New Jersey, DeltaMed Solutions boasts a team of seasoned professionals with extensive experience serving mid-sized and large pharmaceutical and biotech companies. Their expertise spans data management, biostatistics, programming, real-world evidence solutions, pharmacokinetics/pharmacodynamics analysis, regulatory affairs, and medical affairs. DeltaMed Solutions is renowned for its flexible service models and unwavering commitment to quality, earning high praise from clients and partners alike.

With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.

The integration of DeltaMed Solutions into HiRO creates a powerhouse in the CRO industry. Leveraging the combined expertise of both companies, HiRO can now offer a broader range of services and cater to a wider network of clients. This strategic move strengthens HiRO’s ability to deliver efficient, customized, and cost-effective clinical trial solutions – addressing the unmet R&D needs of pharmaceutical and biotech companies worldwide.

Dr. Karen Chu, Founder and CEO of HiRO, expressed her confidence in the acquisition, stating, “We are delighted to extend a warm welcome to DeltaMed Solutions. This acquisition aligns seamlessly with HiRO’s growth strategy, enhancing our capability to continue delivering exceptional services that exceed industry standards. By combining our resources and expertise, we are strongly positioned to become our clients’ trusted partner in advancing patient treatments and making a lasting impact on the healthcare landscape. This collaboration leverages our collective strengths, ensuring optimal efficiency and effectiveness in conducting clinical trials across a wide range of therapeutic areas in the US, Asia-Pacific, and beyond. This sets us apart as a pioneering force in the highly competitive CRO industry.”

Dr. Sam Liang, President of DeltaMed Solutions, added, “We are thrilled to become an integral part of HiRO and contribute to their continued success. This opportunity allows us to harness our scientific expertise and well-established presence in the US. Working together, we will offer an enriched, globally integrated suite of services to our clients, driven by our shared dedication to quality, innovation, and patient-centric research. This collaboration will streamline processes and accelerate the development of groundbreaking treatments.”

With the acquisition of DeltaMed Solutions, HiRO and the combined team are positioned to provide an unmatched range of services. Their shared vision for excellence in clinical research will contribute significantly to advancements in healthcare and pharmaceutical innovation.